Therefore, intact MGMT protein in relation to TMZ therapy provides therapeutic detrimental protective impact and conversely is confirmed not to be present when MGMT protein is lost owing to epigenetic silencing of its promoter as seen in various tumors in particular glioma, thus rendering cells more sensitive to alkylating agents. Here, MGMT is linked to central nervous system cancer.